Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7022684 | 0.95 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7011889 | 0.95 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7103501 | 0.94 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7017881 | 0.94 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7018781 | 0.93 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7026336 | 0.93 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7020429 | 0.93 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7023964 | 0.92 | ALDH1A1 (0.65) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7021872 | 0.91 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL7020235 | 0.91 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9AKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | claimed |
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2015035027-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | NR1H2, NR1H3, RXRB | ALDH1A1 1132/4885NPC1 86/4885RAB9A 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.